Validating Biomarkers for the Prodrome and Transition to Psychosis in Shanghai

描述（由申请人提供）：“上海市前驱症状和向精神病过渡的生物标志物验证”项目摘要/摘要：识别精神分裂症发展风险人群是制定精神分裂症早期干预和预防策略的核心。在澳大利亚、欧洲和北美（“北美前驱期纵向研究/NAPLS”）的研究人员领导下，在假定的前驱期、临床高风险（CHR）阶段的人群研究中有一项世界性的运动。在亚洲早期精神病网络，台湾和新加坡已经开始解决推定的前驱人群。据我们所知，我们是唯一一个与上海精神卫生中心（SMHC）合作开展CHR研究的小组，R21, MH093294 （Fogarty/NIH，“将精神病前驱症状的调查扩大到不同文化群体”）。初步研究已经开始，包括四个主要组成部分：a)使用前驱症状结构化访谈和前驱症状量表（SIPS/SOPS）对前驱症状受试者进行临床评估（由R21的PI翻译成中文，李医生）；b)使用matrix电池进行神经认知评估，c)病耻感，d)事件相关电位。此外，血液样本将被收集和储存，以供未来的基因分析。作为对RFA-AI-12-021的回应，我们目前的提议是：“美中生物医学合作研究项目（R01）”将以SMHC的R21为基础，通过大幅扩大样本并引入磁共振成像（MRI）的结构、DTI和静息状态测量来扩展R21。我们将与SMHC的研究人员合作，在中国设计和启动一个可持续的CHR到精神病的纵向研究项目。SMHC是世界卫生组织指定的精神卫生研究中心，拥有优秀的临床和生物医学研究技术资源，可以与美国团队合作开展一流的研究。我们的具体目标是：1。鉴别CHR与对照组的临床和生物标志物异常；2. 从NAPLS研究中复制精神病预测算法；3. 表现出越来越多的大脑异常并转化为精神病。200名CHR和100名对照，年龄15-45岁，将在基线时进行评估并随访一年，估计有40名转化为精神病。估计保留率为75%，30名精神病患者，120名非精神病患者和75名对照组将在转化或1年随访时进行评估，并进行广泛的临床和生物学测量。

DESCRIPTION (provided by applicant): "Validating Biomarkers for the Prodrome and Transition to Psychosis in Shanghai" 7. Project Summary/Abstract: The identification of people at risk of developing psychosis is central to the development of early intervention and prevention strategies for schizophrenia. There is a worldwide movement in the study of populations at the putatively prodromal, clinical high-risk (CHR) stage led mainly by researchers in Australia, Europe, and North America ("North American Prodrome Longitudinal Studies/NAPLS). Within the Asian Network for Early Psychosis, Taiwan and Singapore have started to address the putatively prodromal population. To our knowledge, we are the only group carrying out a CHR study, an R21 in collaboration with the Shanghai Mental Health Center (SMHC), MH093294 (Fogarty/NIH, "Broadening the Investigation of Psychosis Prodrome to Different Cultural Groups"). The preliminary study, which has already begun, contains four major components: a) clinical assessment of prodromal subjects using the Structured Interview for Prodromal Syndromes and Scale of Prodromal Symptoms (SIPS/SOPS) (translated into Chinese by the PI of the R21, Dr. Li); b) neurocognitive assessment with the MATRICS battery, c) stigma, and d) event related potentials. In addition, blood samples will be collected and stored for future genetic analyses. Our current proposal, in response to the RFA-AI-12-021: "U.S.-China Program for Biomedical Collaborative Research (R01)" will build upon and extend the R21 at the SMHC by expanding the sample substantially and bring in structural, DTI and resting state measures of magnetic resonance imaging (MRI). We will work collaboratively with researchers at the SMHC to design and initiate a sustainable CHR to psychosis longitudinal program of research in China. The SMHC, a World Health Organization designated research center for mental health, has excellent clinical and biomedical research technical resources that can carry out a first-rate study in collaboration with the US team. Our specific aims are to: 1. Identify clinical and biomarker abnormalities in CHR vs. Controls; 2. Replicate prediction of psychosis algorithms from the NAPLS study and; 3. Demonstrate increasing brain abnormalities with conversion to psychosis. Two hundred CHR and 100 controls, age 15-45, will be assessed at baseline and followed for one year, resulting in an estimated 40 converters to psychosis. With an estimated retention rate of 75%, 30 CHR who become psychotic, 120 who do not become psychotic and 75 controls will be assessed at conversion or 1 year follow-up with an extensive battery of clinical and biological measures.